Is Ciprofloxacin Safe to Take During Pregnancy?

Ciprofloxacin is generally avoided during pregnancy, but the human evidence accumulated over the past three decades is more reassuring than many patients and even some clinicians expect. Multiple large cohort studies and two independent meta-analyses have found no significant increase in major birth defects when ciprofloxacin or other fluoroquinolones are used during the first trimester. The drug does cross the placenta and reaches the fetus, and animal studies have consistently shown cartilage damage in young, growing joints, which is the primary reason fluoroquinolones carry precautionary labels. That gap between alarming animal findings and relatively calm human data is what makes this topic confusing, and worth understanding in detail.

What the Birth Defect Studies Actually Show

The concern that ciprofloxacin might cause structural problems in a developing baby has been studied repeatedly since the 1990s. A multicenter prospective study comparing pregnant women exposed to fluoroquinolones in the first trimester with matched controls found that the rate of major malformations was about 2.2% in the exposed group versus 2.6% in controls, with no meaningful difference between them.¹ A larger Danish cohort study looking specifically at first-trimester fluoroquinolone exposure found a major birth defect rate of 2.4%, with an adjusted odds ratio of 0.91, meaning no increase compared to unexposed pregnancies.² More recently, a Japanese study using integrated databases from two institutions reported a major congenital anomaly rate of 1.5% in the fluoroquinolone group compared to 2.0% in an infection-matched control group and 1.6% in a nonteratogenic control group, with statistical modeling showing fluoroquinolone exposure was not a significant risk factor.³

These individual studies are backed up by pooled analyses. A systematic review and meta-analysis covering eight cohort and two case-control studies found no significant increase in major malformations for quinolones as a class, for fluoroquinolones specifically, or for ciprofloxacin on its own.⁴ A separate meta-analysis reached the same conclusion, with a pooled odds ratio for birth defects of 0.89 after first-trimester quinolone exposure.⁵ In plain terms, the combined weight of the available controlled evidence does not point to ciprofloxacin causing structural birth defects in humans.

Miscarriage Risk

Whether ciprofloxacin might trigger miscarriage is a separate question from birth defects, and it has its own body of evidence. A nationwide Danish cohort study that looked specifically at ciprofloxacin-exposed pregnancies found a miscarriage rate of 8.3% among exposed women compared to 8.7% among unexposed women, yielding a hazard ratio of 0.99, which is essentially identical.⁶ The large Danish fluoroquinolone cohort study mentioned earlier also found no increased risk of spontaneous abortion, with an adjusted hazard ratio of 1.01.⁷

There is, however, a wrinkle. A pharmacovigilance study that mined the FDA’s adverse event reporting system (FAERS) found a disproportionately high signal for spontaneous abortions associated with ciprofloxacin compared both to all other drugs and to other fluoroquinolones.⁸ This kind of database analysis detects unusual clustering of reports but cannot prove causation. Adverse event reports are voluntary, uncontrolled, and subject to reporting bias: doctors and patients who already worry about fluoroquinolones in pregnancy may be more likely to file a report when a miscarriage occurs. When controlled cohort studies, which are better designed to isolate an actual causal effect, find no increased risk, most clinicians weigh the cohort data more heavily. Still, the FAERS signal means the question is not completely closed, and it is one reason ongoing monitoring continues.

Why the Cartilage Worry Persists

The reason ciprofloxacin is flagged during pregnancy in the first place has little to do with human birth defect data and everything to do with what happens in young animal joints. Fluoroquinolones consistently damage developing cartilage in animal models. In immature rats, ciprofloxacin causes joint cartilage lesions that appear to be driven by interference with magnesium availability in the cartilage cells; feeding rats a magnesium-deficient diet alone can produce identical damage.⁹ In lamb models, fluoroquinolones produce visible blistering and fissuring of the joint surface, leading to erosion and arthropathy.¹⁰

These findings are robust and reproducible across species. The logical worry is that a drug known to damage immature cartilage in animals could harm a developing human fetus’s cartilage or, after birth, the joints of a breastfed infant. But human data has not confirmed this leap. Reviews of ciprofloxacin use during pregnancy have not demonstrated increased musculoskeletal harm in exposed children, and follow-up studies of children who received fluoroquinolones directly (at much higher exposure than a fetus would get in utero) have not found lasting joint damage.¹¹ The disconnect likely reflects dose differences, exposure duration, and species-specific cartilage physiology. Animal studies use sustained, high-dose exposures that don’t match a typical short course in a pregnant woman. But because the animal signal is so clear, regulators have kept the precautionary label in place, and most guidelines steer clinicians toward safer-established alternatives when one is available.

How Much Reaches the Fetus

Ciprofloxacin does cross the placenta, so a fetus is exposed to the drug when the mother takes it. A perfusion study using human term placentas found that ciprofloxacin appeared in the fetal compartment at a concentration roughly 22% of the maternal level after three hours, gradually rising to about 53% over a longer period.¹² The transfer was described as slow and constant, indicating moderate fetal exposure rather than a sudden flood. The same study found that ciprofloxacin accumulates in placental tissue itself, which could extend how long the fetus is exposed even after the mother’s blood levels drop.

An earlier in-vitro placental perfusion study reported a lower transplacental transfer percentage of about 3.2%, with a transfer index roughly a third of the reference marker used.¹³ The difference between these two numbers likely reflects different experimental setups, perfusion durations, and measurement timepoints. What both studies agree on is that ciprofloxacin crosses to the fetal side at a slower rate than many other drugs, and the fetal concentration is substantially lower than the maternal concentration. That relatively limited crossing may partly explain why the animal cartilage damage, which requires sustained high drug levels, has not shown up in human birth outcome studies.

Preterm Birth and Fetal Growth

Beyond structural defects, researchers have looked at whether ciprofloxacin exposure affects fetal growth or the timing of delivery. A meta-analysis pooling data from multiple studies found no significant association between first-trimester quinolone exposure and preterm birth or low birth weight.¹⁴ However, a Chinese study that measured antibiotic residues in pregnant women found that higher first-trimester ciprofloxacin levels were associated with a slight reduction in gestational age (about 0.17 days per unit increase) and a marginally elevated odds ratio for preterm birth.¹⁵ That study was measuring environmental-level antibiotic exposure (from food, water, and ambient sources) rather than therapeutic doses prescribed by a doctor, so its relevance to a woman taking a prescribed course is uncertain. The meta-analytic evidence, which directly addresses prescription use, is more reassuring on this point.

When Doctors Prescribe It Anyway

If ciprofloxacin is generally avoided, why would it ever come up during pregnancy? The answer usually involves infections where safer alternatives have failed or are not an option. Urinary tract infections are common in pregnancy and can progress to kidney infections that threaten both mother and baby. Most guidelines recommend first-line antibiotics like nitrofurantoin, amoxicillin, or cephalosporins for UTIs in pregnancy. A review of international guidelines found that France was the only country to include ciprofloxacin, listing it as a third-line option for pregnant women with beta-lactam allergies and as a first-line choice against extended-spectrum beta-lactamase-producing bacteria.¹⁶ In other words, it is a fallback, not a first choice, reserved for situations where the bacteria are resistant to everything else or the patient cannot tolerate safer drugs.

The other major scenario is anthrax. In the event of a bioterror attack or occupational exposure, ciprofloxacin is actually the preferred antibiotic for pregnant women receiving post-exposure prophylaxis, chosen over doxycycline. Federal guidance made this recommendation based on the reasoning that the known risks of untreated anthrax vastly outweigh the theoretical fetal risks of ciprofloxacin, and human data have not validated the animal cartilage concerns.¹⁷ A systematic review of anthrax antibiotics in pregnancy reached a similar conclusion, finding no human studies that validated the cartilage concerns and noting that available data suggest it is unlikely ciprofloxacin poses substantial fetal safety risks.¹⁸ That same review flagged an open question about dosing, noting that pregnant women may need higher or more frequent doses because their kidneys clear drugs faster during pregnancy.

The Misperception Problem

One of the more striking findings in the meta-analytic literature has nothing to do with biology and everything to do with how risk perception shapes outcomes. One of the systematic reviews found that while ciprofloxacin exposure was not associated with a significant increase in major malformations or most adverse outcomes, it was associated with a significantly decreased live birth rate and an increased rate of elective termination. The authors interpreted this not as evidence that ciprofloxacin harms pregnancies, but as a sign that some women and clinicians, believing the drug to be more dangerous than the evidence supports, chose to terminate otherwise healthy pregnancies.¹⁹ This is a real consequence of overstating risk. If a woman takes ciprofloxacin before realizing she is pregnant, the data available suggests that her baby’s risk of birth defects is not meaningfully different from baseline. Making an irreversible decision based on fear rather than evidence is, in this case, the greater harm.

Signals from Adverse Event Databases

Pharmacovigilance databases like the FDA’s FAERS collect spontaneous reports from patients and health-care providers after a drug is on the market. A large analysis of FAERS data found statistically disproportionate reporting of several pregnancy-related adverse events tied to fluoroquinolones, with ciprofloxacin generating 12 significant signals compared to all other drugs. These included elevated reporting odds ratios for spontaneous abortions, congenital connective tissue disorders, congenital coagulation disorders, and genetic mitochondrial abnormalities.²⁰ Ciprofloxacin also showed elevated signals for spontaneous abortions and connective tissue disorders when compared specifically to other fluoroquinolones, suggesting it may carry higher risk within its own drug class.

These findings sound alarming in isolation, but FAERS analysis has well-known limitations. Reports are voluntary and unverified, there are no control groups, confounding by indication (meaning sicker patients get certain drugs) is unavoidable, and duplicate reports can inflate signals. Disproportionality in a database tells you where to look more carefully; it does not prove the drug caused the problem. When the controlled cohort studies and meta-analyses reviewed earlier consistently find no increased risk of birth defects or miscarriage, most experts regard the FAERS signals as hypothesis-generating rather than definitive. The connective tissue signal is biologically plausible given what we know from animal cartilage studies, which is why it merits continued investigation rather than dismissal.

Ciprofloxacin and Breastfeeding

For women who need ciprofloxacin after delivery, a related worry is whether the drug gets into breast milk and could harm a nursing infant. Ciprofloxacin does appear in breast milk. A case report measuring milk concentrations after a single 500-mg oral dose found levels that remained fairly stable over 16 hours.²¹ Pharmacokinetic modeling has estimated a milk-to-plasma ratio of roughly 1.2 for ciprofloxacin, meaning the concentration in milk is slightly higher than in the mother’s blood at steady state.²²

Despite being present in milk, the absolute amount an infant would ingest is small. A review in Canadian Family Physician concluded that although concerns about joint toxicity exist in theory, the amounts excreted into breast milk are low and studies report no substantial increase in joint-related harm even when ciprofloxacin is given directly to infants and children at systemic doses far exceeding what a breastfed baby would receive. The review concluded that interrupting breastfeeding during ciprofloxacin treatment appears unnecessary.²³ Some practitioners still recommend monitoring the infant for diarrhea or thrush, since any antibiotic reaching the gut can disrupt normal flora, but the cartilage concern that dominates the pregnancy conversation does not appear to carry the same weight during breastfeeding.

Dosing Uncertainty in Pregnant Women

An underappreciated issue with ciprofloxacin in pregnancy is that we don’t have well-established dosing for pregnant patients. Pregnancy changes how the body handles drugs: blood volume increases, kidney filtration speeds up, and the liver’s metabolic activity shifts. For a drug like ciprofloxacin that is primarily cleared through the kidneys, faster renal clearance during pregnancy means the drug may leave the body more quickly, potentially dropping below effective concentrations at standard doses. The systematic review on anthrax prophylaxis in pregnancy highlighted that limited pharmacokinetic data suggest pregnant women may require higher or more frequent doses of fluoroquinolones.²⁴ This creates a practical dilemma: a clinician who decides the benefit justifies using ciprofloxacin in a pregnant patient still faces uncertainty about whether the standard dose will work, but has little data to guide an adjusted regimen.

What to Do If You Took It Before Knowing You Were Pregnant

This is one of the most common reasons people search for information about ciprofloxacin and pregnancy. A woman prescribed the drug for a UTI or other infection may discover a few weeks later that she was in early pregnancy during treatment. The evidence reviewed here is directly relevant to that situation: multiple cohort studies and two meta-analyses looking specifically at first-trimester exposure have found no significant increase in birth defects, miscarriage, preterm birth, or low birth weight. The rate of major malformations in exposed groups has consistently hovered around 1.5% to 2.4%, which falls within the normal background rate for the general population. The Danish cohort study, which specifically tracked ciprofloxacin-exposed pregnancies, found a miscarriage rate statistically indistinguishable from unexposed pregnancies.²⁵ None of this data suggests that inadvertent early exposure is a reason to consider termination, and at least one research team has explicitly flagged the danger of overreacting to a perceived risk that the controlled evidence does not support.²⁶ Your obstetrician can review your specific situation, but the population-level data is reassuring.